ACM
MPLT

ADAR1 Capital Management’s MapLight Therapeutics MPLT Stock Holding History

ADAR1 Capital Management’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.62M Buy
+374,909
New +$6.71M 0.45% 53

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ADAR1 Capital Management's MPLT Position: Q1 2026 in Review

ADAR1 Capital Management opened a new position in MapLight Therapeutics (MPLT) in Q1 2026: 374,909 shares worth $7.62M. The stake represents 0.45% of the portfolio and ranks #53 among its holdings.

81 funds tracked by Wall St. Rank hold MPLT as of Q1 2026.

  • ADAR1 Capital Management held 374,909 shares of MapLight Therapeutics worth $7.62M as of Q1 2026.
  • MapLight Therapeutics was a new ADAR1 Capital Management position in Q1 2026.
  • MapLight Therapeutics made up 0.45% of ADAR1 Capital Management's portfolio in Q1 2026, its #53 holding.
  • 81 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.